Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 539-544 , December 2009

Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer

  • Shreerang A. Bhide

      Affiliations

    • The Institute of Cancer Research, London, UK
    • The Royal Marsden NHS Foundation Trust Hospital, London, UK
    • Corresponding Author InformationCorresponding author. Address: Royal Marsden Hospital, Head and Neck Oncology Unit, Fulham Road, London SW3 6JJ, UK.
    • ,
  • Sarah Gulliford

      Affiliations

    • The Institute of Cancer Research, London, UK
    • ,
  • Rehan Kazi

      Affiliations

    • The Royal Marsden NHS Foundation Trust Hospital, London, UK
    • ,
  • Iman El-Hariry

      Affiliations

    • The Royal Marsden NHS Foundation Trust Hospital, London, UK
    • ,
  • Kate Newbold

      Affiliations

    • The Royal Marsden NHS Foundation Trust Hospital, London, UK
    • ,
  • Kevin J. Harrington

      Affiliations

    • The Institute of Cancer Research, London, UK
    • The Royal Marsden NHS Foundation Trust Hospital, London, UK
    • ,
  • Christopher M. Nutting

      Affiliations

    • The Royal Marsden NHS Foundation Trust Hospital, London, UK

Received 23 May 2009 ,Revised 29 September 2009 ,Accepted 30 September 2009.

References 

  1. Bourhis JAC, Pignon J-P. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol. 2004;22:5505
  2. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949–955
  3. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–1715
  4. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil–mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005;23:1125–1135
  5. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665–4673
  6. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol. 2002;20:3964–3971
  7. Nguyen NP, Sallah S, Karlsson U, Antoine JE. Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues. Cancer. 2002;94:1131–1141
  8. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161–1171
  9. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003;21:320–326
  10. Caglar HB, Tishler RB, Othus M, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:1110–1118
  11. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?. Int J Radiat Oncol Biol Phys. 2004;60:1425–1439
  12. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose–effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007;68:1289–1298
  13. Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol. 2007;85:74–82
  14. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose–effect relationship. Radiother Oncol. 2007;85:64–73
  15. Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys. 2009;73:1187–1195
  16. Chen AY, Frankowski R, Bishop-Leone J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M.D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001;127:870–876
  17. Bhide S, Clark C, Harrington K, Nutting CM. Intensity modulated radiotherapy improves target coverage and parotid gland sparing when delivering total mucosal irradiation in patients with squamous cell carcinoma of head and neck of unknown primary site. Med Dosim. 2007;32:188–195
  18. Guerrero Urbano MT, Clark CH, Kong C, et al. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin Oncol (R Coll Radiol). 2007;19:604–613
  19. Gregoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006;79:15–20
  20. Gregoire V, Levendag P, Ang KK, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol. 2003;69:227–236
  21. Humphreys M, Guerrero Urbano MT, Mubata C, et al. Assessment of a customised immobilisation system for head and neck IMRT using electronic portal imaging. Radiother Oncol. 2005;77:39–44
  22. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1:187–191
  23. Bentzen SM, Baumann M. The linear quadratic model in clinical practice. In:  Steel GG editors. Basic clinical radiobiology. 3rd ed.. London: Arnold; 2002;p. 134–146
  24. Langendijk JA, Doornaert P, Rietveld DH, Verdonck-de Leeuw IM, Rene Leemans C, Slotman BJ. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol. 2009;90:189–195
  25. Scripture CD, Figg WD, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2006;4:165–172
  26. Pauloski BR, Logemann JA, Rademaker AW, et al. Speech and swallowing function after oral and oropharyngeal resections: one-year follow-up. Head Neck. 1994;16:313–322
  27. Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2009;
  28. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol. 1998;46:135–146
  29. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–940
  30. Cottrill CP, Bishop K, Walton MI, Henk JM. Pilot study of nimorazole as a hypoxic-cell sensitizer with the “chart” regimen in head and neck cancer. Int J Radiat Oncol Biol Phys. 1998;42:807–810
  31. Henk JM, Bishop K, Shepherd SF. Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol. 2003;66:65–70
  32. Denham JW, Peters LJ, Johansen J, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?. Radiother Oncol. 1999;52:157–164
  33. Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer. 2008;99:57–62
  34. Bentzen SM, Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol. 1994;4:68–80
  35. Screnci D, McKeage MJ. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem. 1999;77:105–110

☆ This manuscript was presented as an abstract at the ESTRO 2008 meeting in Gothenburg.

PII: S0167-8140(09)00565-9

doi: 10.1016/j.radonc.2009.09.017

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 539-544 , December 2009

Article Tools

* Image Usage & Resolution